Advertisement

AAPS PharmSciTech

, 20:86 | Cite as

Sustained Release Bilayer Tablet of Ibuprofen and Phenylephrine Hydrochloride: Preparation and Pharmacokinetics in Beagle Dogs

  • Chunli Zhu
  • Siyuan Xu
  • Xiaopeng Han
  • Wei Wang
  • Wei He
  • Lifang Yin
  • Lei YangEmail author
  • Chao QinEmail author
Research Article
  • 30 Downloads

Abstract

Cold is a global common infectious disease accompanied by symptoms such as headache and stuffy nose. Ibuprofen (IBU) and phenylephrine hydrochloride (PE) were commonly used for common cold due to their different effects in relieving fever and the main symptoms such as nasal congestion and high sinus pressure. However, the commercial tablets of IBU and PE have to be administered 2 to 3 times per day due to their short half-life, with inconvenience for patient and fluctuations of plasma concentration. Bilayer tablet technology was utilized to design the IBU-PE sustained release tablets because of the significantly different solubility of IBU and PE in release media. The formulations of IBU layer and PE layer contain different viscosity grades of hydroxypropyl methylcellulose (HPMC) as sustained-release matrix, hydrophilic diluent, and traditional glidant and lubricant. The sustained release bilayer tablet exhibited satisfying sustained release performance with the mechanisms of diffusion and matrix erosion. Compared with the conventional tablets, the IBU-PE sustained release bilayer tablet expressed significantly sustained-release behavior with decreased Cmax and prolonged Tmax in fasted conditions for IBU and PE. Though IBU of IBU-PE sustained release bilayer tablet was bioequivalent to the commercial IBU tablet, the relative bioavailability of PE from the bilayer tablets was 87.49 ± 20.00% (90% confidence interval was 72.3 to 102.5%), indicating bioinequivalence probably due to the “first pass” effect.

KEY WORDS

ibuprofen phenylephrine hydrochloride sustained release bilayer tablet pharmacokinetics bioavailability 

Notes

Funding Information

This work was supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2017ZX09101001-004) and National Natural Science Funds for Young Scholar (81503011).

References

  1. 1.
    Simasek M, Blandino DA. Treatment of the common cold. Am Fam Physician. 2007;75(4):515–20.PubMedGoogle Scholar
  2. 2.
    Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat. 1999;(200):1–203.Google Scholar
  3. 3.
    Hsiao J, Cherry D, Beatty P, Rechtsteiner E. National Ambulatory Medical Care Survey: 2007 summary. National health statistics report; no 27. Hyattsville, MD: National Center for Health Statistics; 2010.Google Scholar
  4. 4.
    Hendley JO. The common cold and decongestant therapy. Pediatr Rev. 2011;32(2):47.CrossRefGoogle Scholar
  5. 5.
    Ulbrich H, Dannhardt G. A heterogenous drug class. NSAID: classification and spectrum of action. Pharm Unserer Zeit. 2002;31(2):146–54.CrossRefGoogle Scholar
  6. 6.
    Potthast H, Dressman J, Junginger H, Midha K, Oeser H, Shah V, et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci. 2005;94(10):2121–31.CrossRefGoogle Scholar
  7. 7.
    Greenhalgh DJ, Williams AC, Timmins P, York P. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci. 1999;88(11):1182–90.CrossRefGoogle Scholar
  8. 8.
    Higgins J, Gilmor T, Martellucci S, Bruce R, Brittain H. Analytical profiles of drug substances and excipients. San Diego, London: Academic Press; 2001. p. 265–330.CrossRefGoogle Scholar
  9. 9.
    Food AD. Over-the-counter drugs: establishment of a monograph for OTC cold, cough, allergy, bronchodilator and antiasthmatic products.[21 CFR 341]. Fed Regist. 1976;41:38399–400.Google Scholar
  10. 10.
    Gumbhir K, Mason WD. High-performance liquid chromatographic determination of phenylephrine and its conjugates in human plasma using solid-phase extraction and electrochemical detection. J Pharm Biomed Anal. 1996;14(5):623–30.CrossRefGoogle Scholar
  11. 11.
    Davies NM. Clinical pharmacokinetics of ibuprofen. Clin Pharmacokinet. 1998;34(2):101–54.CrossRefGoogle Scholar
  12. 12.
    Eccles R. Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse. Br J Clin Pharmacol. 2007;63(1):10–4.CrossRefGoogle Scholar
  13. 13.
    Bogan RK. Treatment options for insomnia-pharmacodynamics of zolpidem extended-release to benefit next-day performance. Postgrad Med. 2008;120(3):161–71.CrossRefGoogle Scholar
  14. 14.
    Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S, Nagarajan M. Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem Pharm Bull. 2008;56(10):1455–8.CrossRefGoogle Scholar
  15. 15.
    Efentakis M, Peponaki C. Formulation study and evaluation of matrix and three-layer tablet sustained drug delivery systems based on carbopols with isosorbite mononitrate. AAPS PharmSciTech. 2008;9(3):917–23.CrossRefGoogle Scholar
  16. 16.
    Phaechamud T. Variables influencing drug release from layered matrix system comprising hydroxypropyl methylcellulose. AAPS PharmSciTech. 2008;9(2):668–74.CrossRefGoogle Scholar
  17. 17.
    Maggi L, Segale L, Conti S, Machiste EO, Salini A, Conte U. Preparation and evaluation of release characteristics of 3TabGum, a novel chewing device. Eur J Pharm Sci. 2005;24(5):487–93.CrossRefGoogle Scholar
  18. 18.
    Park CR, Munday DL. Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. Int J Pharm. 2002;237(1):215–26.CrossRefGoogle Scholar
  19. 19.
    Sungthongjeen S, Sriamornsak P, Puttipipatkhachorn S. Design and evaluation of floating multi-layer coated tablets based on gas formation. Eur J Pharm Biopharm. 2008;69(1):255–63.CrossRefGoogle Scholar
  20. 20.
    Hengstmann J, Goronzy J. Pharmacokinetics of 3 H-phenylephrine in man. Eur J Clin Pharmacol. 1982;21(4):335–41.CrossRefGoogle Scholar
  21. 21.
    Cheng L, Li T, Dong L, Wang X, Huo Q, Wang H, et al. Design and evaluation of bilayer pump tablet of flurbiprofen solid dispersion for zero-order controlled delivery. J Pharm Sci. 2018;107(5):1434–42.  https://doi.org/10.1016/j.xphs.2017.12.026.CrossRefPubMedGoogle Scholar
  22. 22.
    Dhiman N, Awasthi R, Jindal S, Khatri S, Dua K. Development of bilayer tablets with modified release of selected incompatible drugs. Polim Med. 2016;46(1):5–15.  https://doi.org/10.17219/pim/62511.CrossRefPubMedGoogle Scholar
  23. 23.
    Qin C, Wu M, Xu S, Wang X, Shi W, Dong Y, et al. Design and optimization of gastro-floating sustained-release tablet of pregabalin: in vitro and in vivo evaluation. Int J Pharm. 2018;545(1–2):37–44.  https://doi.org/10.1016/j.ijpharm.2018.04.011.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang HY, Kong AY, Yang B, Yan LP, Di X. Plasma ibuprofen enantiomers and their pharmacokinetics in Beagle dogs determined by HPLC. Yao Xue Xue Bao. 2015;50(12):1607–12.Google Scholar
  25. 25.
    Gelotte CK, Zimmerman BA. Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Clin Drug Investig. 2015;35(9):547–58.  https://doi.org/10.1007/s40261-015-0311-9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kottala N, Abebe A, Sprockel O, Akseli I, Nikfar F, Cuitiño AM. Characterization of interfacial strength of layered powder-compacted solids. Powder Technol. 2013;239:300–7.  https://doi.org/10.1016/j.powtec.2012.12.028.CrossRefGoogle Scholar
  27. 27.
    Busignies V, Mazel V, Diarra H, Tchoreloff P. Role of the elasticity of pharmaceutical materials on the interfacial mechanical strength of bilayer tablets. Int J Pharm. 2013;457(1):260–7.  https://doi.org/10.1016/j.ijpharm.2013.09.009.CrossRefPubMedGoogle Scholar
  28. 28.
    Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519–47.  https://doi.org/10.1208/s12248-011-9290-9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Chambin O, Champion D, Debray C, Rochat-Gonthier MH, Le Meste M, Pourcelot Y. Effects of different cellulose derivatives on drug release mechanism studied at a preformulation stage. J Controll Release. 2004;95(1):101–8.  https://doi.org/10.1016/j.jconrel.2003.11.009. CrossRefGoogle Scholar
  30. 30.
    Grund J, Korber M, Bodmeier R. Predictability of drug release from water-insoluble polymeric matrix tablets. Eur J Pharm Biopharm: 2013;85(3 Pt A):650–655. doi:  https://doi.org/10.1016/j.ejpb.2013.08.007.
  31. 31.
    Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Controll Release. 2011;154(1):2–19.  https://doi.org/10.1016/j.jconrel.2011.04.002. CrossRefGoogle Scholar
  32. 32.
    Williams RO 3rd, Reynolds TD, Cabelka TD, Sykora MA, Mahaguna V. Investigation of excipient type and level on drug release from controlled release tablets containing HPMC. Pharm Dev Technol. 2002;7(2):181–93.  https://doi.org/10.1081/PDT-120003486.CrossRefPubMedGoogle Scholar
  33. 33.
    Lotfipour F, Nokhodchi A, Saeedi M, Norouzi-Sani S, Sharbafi J, Siahi-Shadbad MR. The effect of hydrophilic and lipophilic polymers and fillers on the release rate of atenolol from HPMC matrices. Farmaco. 2004;59(10):819–25.  https://doi.org/10.1016/j.farmac.2004.06.006.CrossRefPubMedGoogle Scholar
  34. 34.
    Tukaram BN, Rajagopalan IV, Shartchandra PSI. The effects of lactose, microcrystalline cellulose and dicalcium phosphate on swelling and erosion of compressed HPMC matrix tablets: texture analyzer. Iran J Pharm Res: IJPR. 2010;9(4):349.Google Scholar
  35. 35.
    Ahmed TA, Al-Abd AM. Effect of finasteride particle size reduction on its pharmacokinetic, tissue distribution and cellular permeation. Drug Deliv. 2018;25(1):555–63.  https://doi.org/10.1080/10717544.2018.1440446.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Franek F, Fransson R, Thorn H, Backman P, Andersson PU, Tehler U. Ranking in vitro dissolution of inhaled micronized drug powders including a candidate drug with two different particle sizes. Mol Pharm. 2018;15(11):5319–26.  https://doi.org/10.1021/acs.molpharmaceut.8b00796.CrossRefPubMedGoogle Scholar
  37. 37.
    Tahara K, Yamamoto K, Nishihata T. Application of model-independent and model analysis for the investigation of effect of drug solubility on its release rate from hydroxypropyl methylcellulose sustained release tablets. Int J Pharm. 1996;133(1–2):17–27.CrossRefGoogle Scholar
  38. 38.
    He W, Li Y, Zhang R, Wu Z, Yin L. Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: preparation and in vitro/in vivo evaluation. Int J Pharm. 2014;476(1):223–31.CrossRefGoogle Scholar
  39. 39.
    Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–33.CrossRefGoogle Scholar
  40. 40.
    Singhvi G, Singh M. Review: In-vitro drug release characterization models. Int J Pharm Sci Res. 2011;2(1):77–84.Google Scholar
  41. 41.
    Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2–3):139–57.CrossRefGoogle Scholar
  42. 42.
    Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol. 1982;21(4):335–41.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Kang Chuan Ji Pharm TechChina Pharmaceutical UniversityNanjingPeople’s Republic of China
  2. 2.School of PharmacyChina Pharmaceutical UniversityNanjingPeople’s Republic of China

Personalised recommendations